Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/9321
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Autologous stem cell transplantation in multiple myelomy patients <60 vs ≥60 years of age
Other Titles: Autologous stem cell transplantation in multiple myelomy patients <60 vs >/-60 years of age
Author: Reece, D.
Bredeson, C.
Perez, W.
Jagannath, S.
Zhang, M.
Ballen, K.
Elfenbein, G.
Freytes, C.
Gale, R.
Gertz, M.
Gibson, J.
Giralt, S.
Keating, A.
Kyle, R.
Maharaj, D.
Marcellus, D.
McCarthy, P.
Milone, G.
Nimer, S.
Pavlovsky, S.
et al.
Citation: Bone Marrow Transplantation, 2003; 32(12):1135-1143
Publisher: Nature Publishing Group
Issue Date: 2003
ISSN: 0268-3369
1476-5365
Statement of
Responsibility: 
DE Reece, C Bredeson, WS Pérez, S Jagannath, MJ Zhang, KK Ballen, GJ Elfenbein, CO Freytes, RP Gale, MA Gertz, J Gibson, SA Giralt, A Keating, RA Kyle, D Maharaj, D Marcellus, PL McCarthy, GA Milone, SD Nimer, S Pavlovsky, LB To, DJ Weisdorf, PH Wiernik, JR Wingard and DH Vesole
Abstract: The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ≥ the age of 60 (median 63; range 60–73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30–59) years. The two groups were similar except that older patients had a higher ß₂-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4–9) and 1-year treatment-related mortality (TRM) was 9% (6–13) in patients <60 years, compared with 5% (2–10) and 8% (4–14), respectively, in patients ≥60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT >12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.
Keywords: autologous transplantation; older patients; multiple myeloma
Rights: © 2003 Nature Publishing Group
RMID: 0020031642
DOI: 10.1038/sj.bmt.1704288
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.